Stereotaxis, Inc. (STXS)
| Market Cap | 173.55M |
| Revenue (ttm) | 27.10M |
| Net Income (ttm) | -21.22M |
| Shares Out | 82.64M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 301,327 |
| Open | 2.090 |
| Previous Close | 2.090 |
| Day's Range | 2.080 - 2.110 |
| 52-Week Range | 1.330 - 3.290 |
| Beta | 1.36 |
| Analysts | Strong Buy |
| Price Target | 4.50 (+114.29%) |
| Earnings Date | May 13, 2024 |
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage,... [Read more]
Financial Performance
In 2023, Stereotaxis's revenue was $26.77 million, a decrease of -4.89% compared to the previous year's $28.15 million. Losses were -$22.06 million, 12.3% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for STXS stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 114.29% from the latest price.
News
Stereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of Africa
Stereotaxis presents innovative proposal leveraging advanced robotic technology and telerobotic presence to sustainably offer high-quality cardiac ablati
Stereotaxis Reports 2024 First Quarter Financial Results
ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial result...
Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies
ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has ent...
Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
ST. LOUIS, April 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will ...
Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States
ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that regulato...
Stereotaxis Reports 2023 Full Year Financial Results
ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu...
Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology
ST. LOUIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the first treatment of patients ...
Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
ST. LOUIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...
Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter
ST. LOUIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that the first patients have bee...
Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients
LEXINGTON, Ky. and ST. LOUIS, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, and Baptist Health Lexington,...
Stereotaxis to Participate in Piper Sandler 35th Annual Healthcare Conference
ST. LOUIS, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis...
Stereotaxis Reports 2023 Third Quarter Financial Results
ST. LOUIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...
Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States
ST. LOUIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first pati...
Stereotaxis to Report Third Quarter 2023 Financial Results on November 9, 2023
ST. LOUIS, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...
Stereotaxis Robotic Technology to be Featured during 7th Annual Meeting of the Society for Cardiac Robotic Navigation
ST. LOUIS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will p...
Heart Centre Rigshospitalet Enhances Leadership in Patient Care with Adoption of Latest Robotic Technology
ST. LOUIS, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicia...
Overland Park Regional Medical Center Becomes First U.S. Hospital with Two Stereotaxis Robotic Systems for Arrhythmia Treatment
ST. LOUIS, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physician...
Live Long-Distance TeleRobotic Procedures to Highlight Stereotaxis Technology at Asia Pacific Heart Rhythm Symposium
ST. LOUIS, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its techn...
Stereotaxis Reports 2023 Second Quarter Financial Results
ST. LOUIS, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...
Stereotaxis and Abbott Combine Technologies in First Integrated Procedures to Treat Arrhythmia Patients
ST. LOUIS, July 18, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first pati...
Stereotaxis to Report Second Quarter 2023 Financial Results on August 10, 2023
ST. LOUIS, July 17, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...
Stereotaxis to Initiate First-in-Human Trial to Support CE Mark Application of MAGiC Catheter
ST. LOUIS, June 15, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it intend...
Stereotaxis to Participate in 20th Annual Craig-Hallum Institutional Investor Conference
ST. LOUIS, May 25, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fisc...
Advocate Christ Medical Center Extends Leadership in Heart Care with Adoption of Genesis Robotic Technology
ST. LOUIS, May 23, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the first treatment of patient...
Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms
ST. LOUIS, May 19, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott's EnSite™ X EP System with Stereotaxis' Robotic ...